Outcome in prostate cancer: Association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7

• Type: Article in International Scientific Journal
• Date: 2002

Authors

Medeiros, RM (Author) Other; Morais, A (Author) Other; Vasconcelos, A (Author) Other; Costa, S (Author) Other; Pinto, D (Author) Other; Oliveira, J (Author) Other; Ferreira, P (Author) Other; Lopes, C (Author) ICBAS

Journal

Title: Clinical Cancer Research

Vol. 8

Pages: 3433-3437

ISSN: 1078-0432

Publisher: American Association for Cancer Research

Indexing

ISI Web of Knowledge - 50 Citations

Scopus - 59 Citations

Scientific classification

FOS: Medical and Health sciences > Clinical medicine

Other information

Authenticus ID: P-000-MFZ

Abstract (EN): Purpose: The endothelial cell-specific form of nitric oxide synthases (ecNOS) was mapped at 7q35-q36 and plays an important role in vascular development and tumor growth in human prostate cancer. Bone metastasis, clinical T-stage, tumor grade, and serum prostate-specific antigen (PSA) have been shown to have prognostic importance in the outcome of prostate cancer. The purpose of this study was to evaluate ecNOS polymorphism as a genetic indicator of the outcome of the disease. Experimental Design: In this study, we characterized the Glu-Asp298 ecNOS polymorphism in a series of 161 prostate cancer cases. Logistic regression models were used to assess the contribution of these genotypes to prostate cancer progression. Results: For Glu-Asp298 polymorphism, we found that GG genotype was associated to advanced disease [P = 0.020; odds ratio (OR), 2.12; 95% confidence interval (0), 1.124.03] and bone metastasis (P = 0.038; OR, 2.23; 95% Cl, 1.03-4.84). Furthermore, after logistic regression analysis with step-wise routine to identify predictive parameters of metastasis, which included age at diagnosis, advanced stage, GG genotype, high grade, and high serum PSA, we observed that Glu-Asp298-GG genotype (P = 0.004; OR, 7.4; 95% CI, 1.87-29.26), high grade tumor (P = 0.009; OR, 6.15; 95% CI, 1.56-24.17), and high serum PSA (P < 0.001; OR, 245.12; 95% CI, 19.93-3013.90) were significantly associated with bone metastasis. Conclusions: This study demonstrates a strong association between Glu-Asp298-GG genotype as a nitric oxide-related genetic factor and advanced disease and bone metastasization. The establishment of a genetic profile for each patient may be useful in the prediction of the outcome of prostate cancer patients.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5